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Introduction	  
Complement activation related pseudoallergy (CARPA) 
is a new class of hypersensitivity reaction. Unlike IgE-
mediated allergy, these reactions arise without prior 
sensitization and symptoms often lessen or disappear on 
later encounters with the provoking agent. Activation of 
the complement system through the various pathways or 
their combination leads to the generation of 
anaphylatoxins, opsonization, and the formation of the 
membrane attack complex. The outcomes include 
activation of mast cells, polymorphonuclear cells and 
platelets, the release of vasoactive mediators, such as 
thromboxane and histamine, with cardiovascular and 
other effects. 
Several dugs and chemicals were shown to trigger 
CARPA, including particulate radio contrast media, drug 
delivery systems, carbon nanotubes, liposomes (Doxil, 
Ambisome) and micellar solvents, such as Cremophor EL 
in Taxol. The monitoring of CARPA became an 
important aspect in the development of these 
pharmaceuticals. Underlining the importance of this new 
type of hypersensitivity, in vitro and in vivo testing of 
complement activation became a recommended 
toxicology test by the US Food and Drug Administration. 
Utilizing a combination of in vitro and in vivo models for 
detailed understanding of the interaction between 
nanomaterials/nanoparticles and the complement system 
is essential. There is a wide range of in vitro assays 
currently used for biocompatibility testing and to study 
the activation of the various complement pathways in 
human sera. For in vivo tests animal models are the 
closest experimental alternatives to the human conditions. 
The interaction of the complex homeostatic systems is 
kept intact, allowing the analysis of physiological and 
pathophysiologic processes as they occur in a living 
organism. 
Objectives	  
The new generation of micro- and nano-sized drug 
delivery systems may bring an increased risk of 
recognition by the immune system as foreign. It can be 
predicted that CARPA will be a returning safety problem 
in the upcoming age of nanomedicines. Hence, its 
understanding and prevention may become a critical step 
in the R&D of these agents.  
In our attempt to study complement activation by various 
nanoparticles and improve the safety and utility of these 
compounds, we had the following specific aims: 
• Establish an in vivo animal model for the testing of 
complement activation related pseudo-anaphylaxis by 
intravenously administered substances. 
• Identify the benefits of the in vivo model compared to 
in vitro complement testing. 
• Examination of the hemodynamic effects of serial 
intravenous injections of Doxil, a clinically used 
liposomal drug. 
• Based on the observations during in vivo testing of 
Doxil, develop a method for the prevention of 
complement activation related pseudo-anaphylaxis to 
the drug. 
• Evaluate the differences between in vitro and in vivo 
methods for the prediction of complement activation 
related pseudo-anaphylaxis provoked by polyethylene 
imine polymer nanoparticles. 
• Test utility of alternative animal species for studying 
complement activation by nanomedicines. 
Methods	  
In vivo tests of complement activation related 
hemodynamic reactions 
 
Experiments using pigs and dogs were performed at the 
Semmelweis Medical University in Hungary and at the 
Uniformed Services University of the Health Sciences 
(USUHS) in the USA, and were approved by the local 
Animal Subject Review Committees and followed their 
guidelines, treating the animals humanely. Swine were 
sedated with i.m. ketamine and anesthetized with either 
i.v. pentobarbital or isoflurane through an endotracheal 
tube. After instrumentation the following parameters 
were continuously monitored and recorded: pulmonary 
arterial pressure (PAP), systemic arterial pressure (SAP), 
central vnous pressure (CVP), electrocardiogram (EGG), 
heart rate (HR), end-tidal carbon dioxide (ETCO2). Test 
materials were injected through the Swan-Ganz catheter 
into the pulmonary circulation and flushed with 5 ml 
saline solution. Between injections of test and/or 
reference material, a resting period of at least 20 minutes 
was maintained. Experiments with dogs followed the 
same protocol. 
 
In vitro complement assay 
 
Human serum samples from healthy volunteer donors, 
obtained through an institutionally approved phlebotomy 
protocol, were stored at -70°C until use. An ELISA-based 
method for quantification of serum S-protein-bound C 
terminal complex (SC5b-9) and levels of the catalytic 
subunit of Complement factor B (Bb) was performed. 
The test polymers, at the concentration determined to be 
the IC50 value, and control compounds were incubated 
with different human sera for 45 min at 37°C in a shaking 
water bath (shaking rate of 80 rpm). After terminating the 
reaction by adding chilled specimen diluent (provided in 
the ELISA kits) at a 20-fold volume, samples were tested 
for SC5b-9 and Bb levels using the respective ELISA kits 
(TCC and Bb kits, Quidel Co, San Diego, CA), following 
the manufacturer’s instructions. All reactions were tested 
in duplicates. 
Results	  
To test complement-activating properties of Doxil, 12 
pigs were administered 0.01 mg/kg Doxil, the equivalent 
of 0.06385 mg phospholipid per kg bodyweight (0.06385 
mg PL/kg), as first dose. After the injection of Doxil, we 
observed acute pulmonary hypertension in all animals, 
within a few minutes following the injection. The mean 
pulmonary arterial pressure (PAP) increased significantly 
(p=0.0005, n=12) from a median of 16.5 (15-20.25) 
mmHg to 42 (34.5-48) mmHg.  
 
To test whether the first reaction can be repeated with 
subsequent doses, in seven animals the first Doxil 
injection was followed by a second identical dose of 
Doxil injection (0.06385 mg PL/kg). Although the 
change in PAP from a median of 17 (14-19) mmHg to 19 
(16-20) mmHg was statistically significant (p=0.0177, 
n=7), such a slight increase is clinically irrelevant, and 
hence we don’t consider it to be a serious anaphylactic 
reaction. 
 To test whether tolerance can be breached with a higher 
dose, six animals received an additional five-fold bolus 
dose of Doxil (0.31925 mg PL/kg) as a third injection. No 
statistical difference could be shown between pre- and 
post-injection pressures either in the pulmonary arterial 
pressure (17 (12.75-19.5) and 20 (17.75-22.25) mmHg, 
respectively, p=0.625, n=5), or in the systemic arterial 
pressures (89.5 (77.75-97.75) and 86 (74.5-99.75) 
mmHg, respectively, p=0.7865, n=5). 
 
To test whether tolerance is specific to Doxil, we 
administered two sequential doses of the complement 
activator Zymosan (0.5 mg/kg) subsequent to the Doxil 
injections, which both triggered increase in PAP from 17 
to 46 mmHg (p=0.0156, n=7) and from 21 to 50.5 mmHg 
(p=0.0355, n=6) respectively. 
 
To study whether the tachyphylaxis phenomenon can be 
used to prevent severe CARPA reaction provoked by 
Doxil injections, we treated five animals with a relatively 
slow infusion of Doxebo, which is a liposome preparation 
with the same chemical composition as Doxil, with the 
sole difference that it does not encapsulate doxorubicin. 
Netiher the Doxebo infusion (p=0.25), nor the subsequent 
low and high dose Doxil injections (p=4164 and p=0.625, 
respectively, n=5) triggered CARPA. 
 
 
 
 
To examine the in vitro complement activation by various 
polyethileneimine (PEI) polymers and their PEGylated 
derivatives, nineteen series of SC5b-9 ELISA 
measurements were performed in 6 different human sera. 
Only PEI-25kDa caused significant (p=0.0273), dose 
dependent elevation of SC5b-9 in 3 out of the 9 sera, 
while the other substances did not exhibit C activation. 
 
To explore the in vivo complement-activating properties 
of the polymers, 13 pigs were injected with the 
preparations and hemodynamic changes were analyzed. 
All of the tested polymers were active in terms of causing 
significant hemodynamic changes, including a rise of 
PAP, rise or decline of SAP, change of heart rate, and 
ECG alterations. In some cases the reaction was 
practically lethal and required active resuscitation efforts 
to save the animal. However, because of the low number 
of animals per group, it is not possible to perform a 
meaningful statistical analysis of the hemodynamic 
changes provoked by each of the different polymers 
separately. Taking all the animals into account, the 
pulmonary arterial pressure significantly increased after 
the first injection from a median of 14 (12-15.75) to 34 
(19.75-44.75) mmHg (p=0.0039, n=10). The increase 
after the second injections was also significant from 16 
(11.5-21.25) to 28.5 (16.25-43.75) mmHg, (p=0.0059, 
n=10) and there was no difference between the changes 
of PAP after the 1st and 2nd injection (148.8% (31.73-
233.6) vs. 82% (28.27-195.6) increase, respectively; 
p=0.2324, n=10). 
 
To assess the utility of dogs as an in vivo animal model 
for testing complement activation by nanomedicines, we 
studied their hemodynamic reactions to the intravenously 
administered liposomal drug Ambisome. Acute systemic 
hypotension developed after the first injections, SAP 
decreased from a median of 146.5 mmHg to 81 mmHg 
(p=0.0313, n=6). Just like in the pig model, we observed 
tachyphylaxis during repeated administration of the 
liposomes and neither low, nor high doses of Ambisom 
caused change in PAP (p=0.0625 and p=0.0938, 
respectively, n=6) or SAP (p=0.8438 and p=1, 
respectively, n=6).  
 
Conclusions	  
1. First injection of Doxil causes clinically significant 
acute pulmonary arterial hypertension. The porcine 
model is extremely sensitive in terms of immune-
reactivity to this liposomal formulation. The 
hemodynamic changes observed in the animals also 
correspond closely with the signs and symptoms 
presented by sensitive humans during clinical adverse 
events after administration of Doxil 
2. There is tachyphylaxis for subsequent Doxil 
injections and they do not cause clinically significant 
acute pulmonary arterial hypertension or changes in 
systemic blood pressure. The tolerance is maintained 
even at a 5-fold dose. 
3. Tolerization with Doxebo can be used to prevent 
severe CARPA reactions to Doxil. This raises the 
possibility of taking advantage of the phenomenon in 
the clinical setting. Prevention of the adverse, often 
severe hypersensitivity reactions may enable its 
application even in those susceptible individuals who 
otherwise would not be able to benefit from the drug. 
4. Tolerance is specific to Doxebo and Doxil. The rapid 
development of tachyphylaxis suggests that it is not 
related to active buildup of immune memory via 
specific cell activation. Consumption or depletion of 
complement factors can also be ruled out as the 
reactivity to other strong C activators as Zymosan is 
maintained in the liposome-tolerized animals. 
5. PEI-25kDa causes dose-dependent complement 
activation in vitro, while all PEI formulations induce 
CARPA in the pig model. PEI 25kD showed the 
highest reactogenic potential in the porcine model as 
well, and during the limited number of experiments 
with the polymers we have not observed complete 
tachyphylaxis 
6. Dogs exhibit signs of CARPA when administered 
Ambisome, but these differ from the hemodynamic 
reactions in pigs after Doxil injections. The typical 
hemodynamic reaction in dogs to Ambisome is a drop 
in systemic arterial pressure without pulmonary 
arterial pressure changes, while to Zymosan the 
response is acute pulmonary hypertension without 
systemic arterial pressure change. 
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